TruClear™ hysteroscopic tissue removal system
Manage pregnancy loss with a patient-first approach.
To find a better way to manage miscarriage, we need to believe in better care.
Believe in better outcomes.
It's time for a better way for managing miscarriages. One that’s patient first. One that lets you see what you’re treating so you can protect and preserve the uterus.1,2
Find out more reasons why physicians like you are opting for visually guided hysteroscopy over blind D&C to treat patients after early pregnancy loss.
What physicians are saying
Aaron Styer, M.D.
Christine Skiadas, M.D.
Fit for the future − for patients and your practice.
Managing miscarriages with hysteroscopy lets you see-and-treat RPOC. It’s a treatment approach that can offer everyone peace of mind. Here’s how:
What to expect with the TruClear™ hysteroscopic tissue removal system
94%
of patients achieved complete removal of RPOC4
40%
faster operative time vs. hysteroscopic resection approaches such as loop resection5
17%
less risk of post-operative adhesion formation in patients treated with hysteroscopy (13%) vs. D&C (30%)1
Capture products of conception
to test for chromosome abnormalities
(where indicated)3,6
Gain a greater vision for miscarriage management.
When D&C is used to evacuate RPOC, 30% of cases result in intrauterine adhesions versus 13% with hysteroscopic resection.1 Explore our Global Value Dossier to see why visually guided hysteroscopy should be the clear choice for treating RPOC in your practice.
Miscarriage Management mHTR vs. Blind D&C Podcast Episode
Why wait?
Compared with expectant, medical, and surgical intervention such as D&C, hysteroscopy may minimize the need for further intervention after miscarriage1,3 — and help preserve endometrial lining.4
Learn why we believe treatment with direct visualization4 after early pregnancy loss should be the norm.
Our goal: leaving patients better off.
When it comes to their gynecologic health, the care and course of treatment patients receive impacts not only their quality of life today, but for years to come.
Discover how we’re upholding our commitment to deliver better healthcare for women.
Operational Headquarters 710 Medtronic Parkway, Minneapolis, MN 55432-5640 USA
©2026 Medtronic
INDICATION FOR USE:
The TruClear™ system is intended for intrauterine use by trained gynecologists to hysteroscopically resect and remove tissue such as: submucous myomas, endometrial polyps, and retained products of conception.
WARNINGS AND ADVERSE EFFECTS:
Adverse effects for operative hysteroscopy include but are not limited to fluid overload due to intravasation and uterine perforation. [Removal of retained products of conception in the setting of known or suspected placenta acreta, placenta increta, or placenta percreta poses a risk of significant and potentially life-threatening bleeding with the highest risk occurring in the immediate postpartum phase.] Please refer to Instructions for Use (IFU) for complete contraindication and risk information. Residual risks to the patients may include but are not limited to exposure to body fluids, laceration, carcinogen exposure, electric shock, uterine perforation, and air embolism.
CONTRAINDICATIONS:
The TruClear™ hysteroscopic tissue removal system should not be used with pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer.
1. Hooker A, Aydin H, Brölmann H, Huirne J. Long-term complications and reproductive outcome after the management of retained products of conception: a systematic review. Fertil Steril. 2016;105(1):156–164.
2. Hooker, A.B., Thurkow, A. Asherman’s syndrome after removal of placenta remnants: a serious clinical problem. Gynecol Surg 8, 449–453 (2011). https://doi.org/10.1007/s10397-011-0677-5
3. Weinberg S, Pansky M, Burshtein I, Beller U, Goldstein H, Barel O. A pilot study of guided conservative hysteroscopic evacuation of early miscarriage. J Minim Invasive Gynecol. 2021; 28(11):1,860–1,867.
4. Hamerlynck TW, Blikkendaal MD, Schoot BC, Hanstede MM, Jansen FW. An alternative approach for removal of placental remnants: hysteroscopic morcellation. J Minim Invasive Gynecol. 2013;20(6):796-802. doi:10.1016/j.jmig.2013.04.024
5. Hamerlynck TW, van Vliet HA, Beerens AS, Weyers S, Schoot BC. Hysteroscopic morcellation versus loop resection for removal of placental remnants: a randomized trial. J Minim Invasive Gynecol. 2016;23(7):1172-1180.
6. Young S, Miller CE. Hysteroscopic resection for management of early pregnancy loss: a case report and literature review. F S Rep. 2022;3(2):163-167. Published 2022 Mar 10. doi:10.1016/j.xfre.2022.03.002
© 2024 Medtronic. All rights reserved. Medtronic, Medtronic logo and engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 02/2024 US-UW-2300043 – [WF#8851730]